API
< Back to situation

[REVISION HISTORY]

South Korea obesity and diabetes medication regulation

5 recorded revisions of this situation.

What changed

2026-11-19 03:04 UTC → 2026-11-20 02:10 UTC · added removed

In late October 2026, the South Korean Ministry of Food and Drug Safety expanded the approved indications for Mounjaro (tirzepatide). The medication is now approved for adult type 2 diabetes patients with established cardiovascular disease to reduce the risk of major adverse cardiovascular events, as well as for pediatric patients aged 10 and older to improve glycemic control. By mid-November 2026, South Korean authorities further relaxed customs policies regarding obesity treatments. Effective November 12, 2026, travelers are permitted to personally carry medications such as Wegovy and Mounjaro that were legally prescribed and purchased abroad for personal use, up to a three-month supply. This relaxation has intensified the “Sushijaro” trend, where South Koreans travel to Japan to purchase Mounjaro because it costs approximately one-fourth of the price in South Korea. This trend is fueled by a weak Japanese yen and the availability of Japanese telemedicine services that offer delivery to hotels. Digital tools, including apps that compare Japanese hospital prices and locations, have emerged to facilitate these trips. In response to concerns over illegal smuggling and unregulated prescription tourism, the Ministry of Food and Drug Safety established a special task force to combat the illegal distribution of GLP-1 class obesity treatments. The task force is monitoring social media, blogs, and second-hand marketplaces to identify illegal advertisements, brokerage, and peer-to-peer sales. Authorities emphasized that while importing medication for personal use is permitted, reselling these drugs or giving them away for free within South Korea violates the Pharmaceutical Affairs Act. Violators face up to five years in prison or fines of up to 50 million won. Health authorities continue to warn of potential side effects, such as non-arteritic anterior ischemic optic neuropathy (NAION).

Versions

  1. 2026-11-20 02:10 UTC South Korea obesity and diabetes medication regulation
  2. 2026-11-19 03:04 UTC South Korea obesity and diabetes medication regulation
  3. 2026-11-15 06:43 UTC South Korea obesity and diabetes medication regulation
  4. 2026-11-13 00:21 UTC South Korea obesity and diabetes medication regulation
  5. 2026-11-12 10:24 UTC South Korea obesity and diabetes medication regulation
  6. 2026-11-11 16:45 UTC South Korea obesity and diabetes medication regulation

Select a version to see what changed compared to the one before it.